Judith Favier

List of Publications by Year
in descending order

97 papers	8,509 citations	50276 46 h-index	43889 91 g-index
113 all docs	113 docs citations	113 times ranked	7540 citing authors

#	Article	IF	Citations
1	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
2	SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics, 2010, 19, 3011-3020.	2.9	604
3	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	10.7	477
4	Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research, 2003, 63, 5615-21.	0.9	409
5	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology, 2015, 11, 101-111.	9.6	396
6	The R22X Mutation of the SDHD Gene in Hereditary Paraganglioma Abolishes the Enzymatic Activity of Complex II in the Mitochondrial Respiratory Chain and Activates the Hypoxia Pathway. American Journal of Human Genetics, 2001, 69, 1186-1197.	6.2	339
7	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics, 2014, 23, 2440-2446.	2.9	316
8	Angiopoietin-Like 4 Is a Proangiogenic Factor Produced during Ischemia and in Conventional Renal Cell Carcinoma. American Journal of Pathology, 2003, 162, 1521-1528.	3.8	287
9	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics, 2011, 20, 3974-3985.	2.9	266
10	SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1472-E1476.	3.6	257
11	Functional Consequences of aSDHBGene Mutation in an Apparently Sporadic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4771-4774.	3.6	210
12	The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLoS ONE, 2009, 4, e7094.	2.5	203
13	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5.5	176
14	Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nature Communications, 2015, 6, 8784.	12.8	169
15	Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood, 2005, 105, 1523-1530.	1.4	159
16	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	5.1	155
17	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
18	Mitochondrial succinate is instrumental for HIF1Î± nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Molecular Genetics, 2005, 14, 3263-3269.	2.9	146

#	Article	IF	Citations
19	Angiogenesis and Vascular Architecture in Pheochromocytomas. American Journal of Pathology, 2002, 161, 1235-1246.	3.8	137
20	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
21	Oncometabolitesâ€driven tumorigenesis: From genetics to targeted therapy. International Journal of Cancer, 2014, 135, 2237-2248.	5.1	119
22	An overview of 20Âyears of genetic studies in pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101416.	4.7	106
23	A Decade (2001-2010) of Genetic Testing for Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 359-366.	1.5	103
24	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. Cancer Research, 2018, 78, 1914-1922.	0.9	96
25	Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. American Journal of Physiology - Cell Physiology, 2006, 291, C1114-C1120.	4.6	95
26	Pheochromocytomas: The (pseudo)-hypoxia hypothesis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 957-968.	4.7	94
27	Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E954-E962.	3.6	87
28	Mosaicism inHIF2A-Related Polycythemia-Paraganglioma Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E369-E373.	3.6	87
29	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1109-1118.	3.6	82
30	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2019, 25, 760-770.	7.0	82
31	Succinate dehydrogenase deficiency in human. Cellular and Molecular Life Sciences, 2005, 62, 2317-2324.	5.4	79
32	Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2012, 23, 34-42.	9.0	75
33	Unsuspected task for an old team: Succinate, fumarate and other Krebs cycle acids in metabolic remodeling. Biochimica Et Biophysica Acta - Bioenergetics, 2014, 1837, 1330-1337.	1.0	66
34	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. Journal of Medical Genetics, 2019, 56, 513-520.	3.2	60
35	Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood, 2005, 105, 103-110.	1.4	59
36	HIF2AMutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012, 367, 2161-2162.	27.0	59

#	Article	IF	Citations
37	Hereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency. Hormone Research in Paediatrics, 2005, 63, 171-179.	1.8	57
38	RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 376-379.	1.9	55
39	In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. Clinical Cancer Research, 2016, 22, 1120-1129.	7.0	54
40	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	10.0	54
41	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
42	Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget, 2015, 6, 32955-32965.	1.8	52
43	VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood, 2004, 103, 3789-3797.	1.4	50
44	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene, 2016, 35, 1080-1089.	5.9	50
45	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2Î±-Driven Mesenchymal Transition. Cell Reports, 2020, 30, 4551-4566.e7.	6.4	49
46	Critical overexpression of thrombospondin 1 in chronic leg ischaemia. Journal of Pathology, 2005, 207, 358-366.	4.5	48
47	Cloning and expression pattern of EPAS1 in the chicken embryo. FEBS Letters, 1999, 462, 19-24.	2.8	46
48	A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. European Journal of Endocrinology, 2011, 164, 141-145.	3.7	46
49	SDHD Immunohistochemistry: A New Tool to ValidateSDHxMutations in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E287-E291.	3.6	45
50	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
51	Simultaneous positron emission tomography and ultrafast ultrasound for hybrid molecular, anatomical and functional imaging. Nature Biomedical Engineering, 2018, 2, 85-94.	22.5	44
52	Evolutionarily conserved susceptibility of the mitochondrial respiratory chain to SDHI pesticides and its consequence on the impact of SDHIs on human cultured cells. PLoS ONE, 2019, 14, e0224132.	2.5	43
53	Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. Developmental Dynamics, 2001, 222, 377-388.	1.8	39
54	Risk assessment of maternally inheritedSDHDparaganglioma and phaeochromocytoma. Journal of Medical Genetics, 2017, 54, 125-133.	3.2	37

#	Article	IF	Citations
55	Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Science Signaling, 2017, 10, .	3.6	35
56	The genetics of paragangliomas. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2012, 129, 315-318.	0.7	34
57	From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma. Molecular and Cellular Endocrinology, 2016, 421, 40-48.	3.2	34
58	HIF2Î± reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer, 2007, 7, 139.	2.6	33
59	Peritoneal Implantation of Pheochromocytoma Following Tumor Capsule Rupture During Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2681-E2685.	3.6	33
60	Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Modern Pathology, 2022, 35, 352-360.	5.5	33
61	Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paragangliomaâ€"a retrospective and prospective study. Modern Pathology, 2020, 33, 57-64.	5.5	30
62	Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. BMC Biochemistry, 2010, 11, 5.	4.4	26
63	Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. Cancer Research, 2021, 81, 3480-3494.	0.9	26
64	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
65	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
66	Orbital Nonchromaffin Paraganglioma. Ophthalmology, 1989, 96, 1659-1666.	5.2	23
67	A MEN1 syndrome with a paraganglioma. European Journal of Human Genetics, 2014, 22, 283-285.	2.8	23
68	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1510-1517.	6.4	22
69	Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas. Endocrine-Related Cancer, 2020, 27, R451-R463.	3.1	22
70	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites, 2017, 7, 17.	2.9	21
71	Succinate dehydrogenase deficiency in a chromaffin cell model retains metabolic fitness through the maintenance of mitochondrial NADH oxidoreductase function. FASEB Journal, 2020, 34, 303-315.	0.5	17
72	Vascular Endothelial Growth Factor-A Is Associated with Chronic Mountain Sickness in the Andean Population. High Altitude Medicine and Biology, 2014, 15, 146-154.	0.9	16

#	Article	IF	Citations
73	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4764-4768.	3.6	16
74	Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis. Cell and Tissue Research, 2018, 372, 379-392.	2.9	16
75	Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Annales D'Endocrinologie, 2019, 80, 159-162.	1.4	15
76	Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas. PLoS ONE, 2015, 10, e0121361.	2.5	14
77	Concurrent imaging of vascularization and metabolism in a mouse model of paraganglioma under anti-angiogenic treatment. Theranostics, 2020, 10, 3518-3532.	10.0	12
78	Germline mutations in the new E1â€™ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. Journal of Medical Genetics, 2020, 57, 752-759.	3.2	12
79	Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 898-907.	3.6	11
80	IN SITU HYBRIDIZATION AND IMMUNOGOLD LOCALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 ON THE PERICYTES OF THE CHICK CHORIOALLANTOIC MEMBRANE. Cytokine, 2002, 17, 262-265.	3.2	10
81	The mTORC1 Complex Is Significantly Overactivated in <i>SDHX</i>-Mutated Paragangliomas. Neuroendocrinology, 2017, 105, 384-393.	2.5	10
82	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1301-e1315.	3.6	10
83	Role of MSK1 in the signaling pathway leading to VEGF-mediated PAF synthesis in endothelial cells. Journal of Cellular Biochemistry, 2006, 98, 1095-1105.	2.6	9
84	Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma. Oncotarget, 2017, 8, 51050-51057.	1.8	9
85	An update on adult forms of hereditary pheochromocytomas and paragangliomas. Current Opinion in Oncology, 2021, 33, 23-32.	2.4	9
86	Sunitinib-induced cardiac hypertrophy and the endothelin axis. Theranostics, 2021, 11, 3830-3838.	10.0	7
87	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
88	International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma. Journal of Medical Genetics, 2022, 59, 785-792.	3.2	5
89	Overexpression of miRâ€483â€5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma. Clinical and Translational Medicine, 2020, 10, e260.	4.0	4
90	Models of pheochromocytoma: what's on the horizon?. International Journal of Endocrine Oncology, 2015, 2, 171-174.	0.4	2

#	Article	IF	Citations
91	Persistent Properties of a Subpopulation of Cancer Cells Overexpressing the Hedgehog Receptor Patched. Pharmaceutics, 2022, 14, 988.	4.5	2
92	Apports de COMETE Ã la gÃ©nÃ©tique du phÃ©ochromocytome. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 105-116.	0.0	1
93	Paragangliome hÃ©rÃ©ditaire : identification d'une nouvelle mutation du gÃ¨ne SDHD impliquÃ© dans la rÃ©ponse Ã l'hypoxie. Revue De Medecine Interne, 2000, 21, 502.	1.0	0
94	VEGF-A-MEDIATED ENDOTHELIAL P-SELECTIN TRANSLOCATION AND NEUTROPHIL ADHESION TO ENDOTHELIAL CELLS: ROLE OF VEGF RECEPTORS AND ENDOGENOUS PAF SYNTHESIS.. Cardiovascular Pathology, 2004, 13, 113.	1.6	0
95	Role of MSK1 in the signaling pathway leading to VEGF-mediated PAF synthesis in endothelial cells. Vascular Pharmacology, 2006, 45, e130.	2.1	0
96	La gÃ©nÃ©tique des paragangliomes. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2012, 129, 357-360.	0.0	0
97	THE HIF-PATHWAY, NEW CANDIDATE GENES FOR PARAGANGLIOMA AND/OR PHEOCHROMOCYTOMA?. Journal of Hypertension, 2004, 22, S77.	0.5	0